Ecnoglutide
About
About Ecnoglutide
Ecnoglutide is a once-weekly GLP-1 receptor agonist developed by Sciwind Biosciences, with Phase III trials ongoing in China and international markets. It has shown efficacy and tolerability comparable to semaglutide in head-to-head Phase II comparisons. It represents the expanding pipeline of GLP-1 agents that may increase global access and competitive pricing in the obesity treatment landscape.
Science
Mechanism of Action
Binds and activates GLP-1 receptors with high affinity and a structural design conferring extended half-life for once-weekly dosing, producing appetite suppression, enhanced insulin secretion, and slowed gastric emptying through canonical GLP-1 signaling pathways.
Dosing
Typical Protocol
Weekly subcutaneous injection; Phase III doses titrated from 2–10 mg weekly.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Ecnoglutide — with trust scores, legal credentials, and pricing transparency.